Ablynx N.v.

Hilde Adi Pierrette Revets

Carlo Boutton

Hendricus Renerus Jacobus Mattheus Hoogenboom

Joost Alexander Kolkman

Gerald Beste

Robert Hofmeister

Bjoern Hock

Jo Vercammen

Augustinus Antonius Maria Silvester Van Dongen

Christine Knuehl

Frank Kamiel Delphina Verdonck

Sigrid Godelieve Victor Cornelis

Stephanie Staelens

Peter Verheesen

Els Beirnaert

Pascal Gérard Merchiers

Augustinus Antonius Maria Silverster Van Dongen

The present disclosure relates to amino acid sequences that are directed against (as defined herein) HER3, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences (also referred to herein as 'amino acid sequences of the invention', 'compounds of the invention', and &#x201c;polypeptides of the invention&#x201d;, respectively). The disclosure also relates to nucleic acids encoding such amino acid sequences and polypeptides (also referred to herein as &#x201c;nucleic acids of the invention&#x201d; or &#x201c;nucleotide sequences of the invention&#x201d;); to methods forpreparing such amino acid sequences and polypeptides; to host cells expressing or capable of expressing such amino acid sequences or polypeptides; to compositions, and in particular to pharmaceutical compositions, that comprise such amino acid sequences, polypeptides, nucleic acids and/or host cells; and to uses of such amino acid sequences or polypeptides, nucleic acids, host cells and/or compositions, in particular for prophylactic, therapeutic or diagnostic purposes, such as the prophylactic, therapeutic or diagnostic purposes mentioned herein.

Biological materials related to HER3

The present invention relates to biological materials against HGF and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the biological materials of the present invention inhibit binding of HGF to its receptor c-Met.

Sequences directed against hepatocyte growth factor (HGF) and polypeptides comprising the same for the treatment of cancers and/or tumors

The present invention relates to amino acid sequences and Nanobodies that are directed against Epidermal Growth Factor Receptor 2 (HER2), as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.

Amino acid sequences directed against HER2 and polypeptides comprising the same for the treatment of cancers and/or tumors

The present disclosure relates to amino acid sequences that are directed against (as defined herein) HER3, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences (also referred to herein as 'amino acid sequences of the invention', 'compounds of the invention', and &#x201c;polypeptides of the invention&#x201d;, respectively). The disclosure also relates to nucleic acids encoding such amino acid sequences and polypeptides (also referred to herein as &#x201c;nucleic acids of the invention&#x201d; or &#x201c;nucleotide sequences of the invention&#x201d;); to methods for 10 preparing such amino acid sequences and polypeptides; to host cells expressing or capable of expressing such amino acid sequences or polypeptides; to compositions, and in particular to pharmaceutical compositions, that comprise such amino acid sequences, polypeptides, nucleic acids and/or host cells; and to uses of such amino acid sequences or polypeptides, nucleic acids, host cells and/or compositions, in particular for prophylactic, therapeutic or diagnostic purposes, such as the prophylactic, therapeutic or diagnostic purposes mentioned herein.

The present invention relates to amino acid sequences that are capable of binding to serum proteins; to compounds, proteins, polypeptides, fusion proteins or constructs comprising or essentially consisting of such amino acid sequences; to nucleic acids that encode such amino acid sequences, compounds, proteins, polypeptides, fusion proteins or constructs; to compositions, and in particular pharmaceutical compositions, that comprise such amino acid sequences, compounds, proteins, polypeptides, fusion proteins or constructs; and to uses of such amino acid sequences, compounds, proteins, polypeptides, fusion proteins or constructs.

Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same

The present invention relates to amino acid sequences that are capable of binding to serum albumin, which sequences do not significantly reduce or inhibit the binding of serum albumin to FcRn or significantly reduce the half-life of serum albumin. It further relates to proteins and polypeptides comprising or essentially consisting of such amino acid sequences; to nucleic acids that encode such amino acid sequences, proteins or polypeptides; to compositions, and in particular pharmaceutical compositions, that comprise such amino acid sequences, proteins and polypeptides; and to uses of such amino acid sequences, proteins and polypeptides.

Growing community of inventors

Meise, Belgium

Hilde Adi Pierrette Revets